Robert Pendergrast

US Patent:

20190255303, Aug 22, 2019

Filed:

Sep 8, 2017

Appl. No.:

16/331180

Inventors:

- Cambridge MA, US
Robert Scott Pendergrast - Chatham NJ, US
John Stephen Pendergrast - Stockholm NJ, US
Anna Irmina Markowska - Brookline MA, US

Assignee:

YMIR GENOMICS LLC - Cambridge MA

International Classification:

A61M 31/00
G01N 1/40

Abstract:

Compositions and methods for the application of non-toxic bioparticle (e.g., extracellular vesicle (EV)) absorbing materials (e.g., non-toxic exosome reducing materials) for prophylactic, therapeutic, validation and/or experimental purposes are provided.

US Patent:

20190040093, Feb 7, 2019

Filed:

Feb 10, 2017

Appl. No.:

16/075844

Inventors:

- Cambridge MA, US
Robert Scott Pendergrast - Chatham NJ, US
John Stephen Pendergrast - Stockholm NJ, US
Anna Irmina Markowska - Brookline MA, US

Assignee:

YMIR GENOMICS LLC - Cambridge MA

International Classification:

C07H 1/06
B01D 9/00
B01D 21/26
C12N 15/10
C07K 1/32
C07H 21/00
C07K 1/36

Abstract:

Compositions and methods for the isolation of protein-nucleic acid complexes, extracellular vesicle (EV) (e.g., microvesicles) and free nucleic acids (collectively referred to as “bioparticles”) released by mammalian cells into body fluids or cell culture media are provided. Isolated bioparticles of the current disclosure contain biomolecules that are useful as diagnostic/prognostic biomarkers or for identification of therapeutic targets (e.g., disease or disorder-associated miRNAs, circulating tumor DNA). Isolation of biomolecules results in purification and concentration. Methods for producing biofluids without detectable bioparticles, largely depleted of bioparticles, and/or possessing a reduced concentration of bioparticles compared to a biofluid starting material (collectively termed “bioparticle-depleted”) are provided. Bioparticle-depleted biofluid is useful, e.g., in experimental systems where desirable to obtain a biofluid lacking or substantially depleted of endogenous bioparticles from the source material. Non-toxic bioparticle absorbing materials (e.g., exosome-reducing materials) can also be used for prophylactic, therapeutic, validation and/or experimental purposes.

US Patent:

20170252670, Sep 7, 2017

Filed:

Aug 5, 2015

Appl. No.:

15/501068

Inventors:

- Cambridge MA, US
Robert Scott Pendergrast - Chatham NJ, US
John Stephen Pendergrast - Stockholm NJ, US
Anna Irmina Markowska - Brookline MA, US

International Classification:

B01D 9/00
G01N 1/40
C12N 15/10
B01D 21/26
C07K 1/30

Abstract:

Compositions and methods for the isolation of protein-nucleic acid complexes and microvesicles (collectively referred to as “bioparticles”) released by mammalian cells into body fluids or cell culture media are provided. Isolated bioparticles of the invention contain biological molecules that are useful as diagnostic/prognostic biomarkers or for identification of therapeutic targets (e.g., disease or disorder-associated miRNAs). The isolation of biological molecules as described herein results in purification and concentration of the molecules. Methods for producing bio fluids that are free of detectable bioparticles, that are largely depleted of bioparticles, or that possess a reduced concentration of bioparticles compared to a bio fluid starting material (collectively termed “bioparticle-depleted”) are also provided. Isolation of bioparticle-depleted biofluid is useful, e.g., in experimental systems where it is desirable to use a biofluid that does not contain endogenous bioparticles, or has been substantially depleted of endogenous bioparticles, from the source material.